MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Deferred Tax Assets / Liabilities | ₹48 Cr | ₹16 Cr | ₹-36 Cr | ₹-40 Cr | ₹-6.57 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of MANKIND PHARMA ?
Year | Deferred Tax Assets / Liabilities |
---|---|
Mar2023 | ₹48 Cr |
Mar2022 | ₹16 Cr |
Mar2021 | ₹-36 Cr |
Mar2020 | ₹-40 Cr |
Mar2019 | ₹-6.57 Cr |
How is Deferred Tax Assets / Liabilities of MANKIND PHARMA Trending?
Years | Deferred Tax Assets / Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹48 Cr | 191.02 | |
Mar2022 | ₹16 Cr | Positive | |
Mar2021 | ₹-36 Cr | Negative | |
Mar2020 | ₹-40 Cr | Negative | |
Mar2019 | ₹-6.57 Cr | - |
Compare Deferred Tax Assets / Liabilities of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹84,588.7 Cr | -6.1% | -11.9% | 54.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹367,290.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
CIPLA | ₹113,357.0 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹111,134.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,235.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,001.5 Cr | -1% | -2.4% | 28.4% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -6.1% |
-11.9% |
54.1% |
SENSEX | 1.7% |
1.5% |
18.7% |
You may also like the below Video Courses